Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Albuterol HFA Clear all
Terminated Phase 3 Interventional

4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma

NCT00634517
View directory record Official record
Conditions
Asthma
Interventions
Armstrong Albuterol Sulfate Inhalation Aerosol, Albuterol Sulfate Inhalation Aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Stockton, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

NCT03364608
View directory record Official record
Conditions
Asthma
Interventions
AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

NCT00268723
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
Levalbuterol tartrate HFA MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Denver, Colorado • Burke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 3 Interventional

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

NCT00144846
View directory record Official record
Conditions
Asthma
Interventions
albuterol sulfate inhalation aerosol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 23 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
27
States / cities
Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects

NCT00685347
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Long Beach, California • Denver, Colorado • Englewood, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 24, 2026, 8:21 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Advair HFA in Healthy and HAPE Predisposed Subjects

NCT06040268
View directory record Official record
Conditions
Altitude Edema
Interventions
Advair HFA, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)

NCT00200967
View directory record Official record
Conditions
Asthma
Interventions
salmeterol, beclomethasone HFA
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

NCT01058863
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax®, ProAir® HFA, Placebo Inhaler
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Huntington Beach, California • Rolling Hills Est., California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 24, 2026, 8:21 PM EDT
Not listed Phase 3 Interventional

Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base

NCT03549897
View directory record Official record
Conditions
Asthma
Interventions
Placebo, 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product
Drug
Lead sponsor
Amneal Ireland Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Brookhaven, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 24, 2026, 8:21 PM EDT
Terminated Phase 3 Interventional

Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients

NCT00635505
View directory record Official record
Conditions
Asthma
Interventions
albuterol HFA (Armstrong's), albuterol HFA (Proventil HFA), HFA placebo
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Mobile, Alabama • Huntington Beach, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 4 Interventional

Non-invasive Measures of Distal Lung Disease in Asthmatics

NCT00250341
View directory record Official record
Conditions
Asthma
Interventions
QVAR, Advair, Servent Diskus
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

NCT00818454
View directory record Official record
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 3 Interventional

Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD

NCT00583986
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, COPD
Interventions
Levalbuterol HFA MDI with top mounted actuation indicator
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Encinatas, California • Huntington Beach, California • Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00909779
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
40 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
73
States / cities
Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 24, 2026, 8:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

NCT01851642
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
Interventions
History and physical exam., Blood draw., Pulmonary function testing., Albuterol inhaler.
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2033
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

NCT01056159
View directory record Official record
Conditions
Asthma
Interventions
Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 3 Interventional

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

NCT06154304
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2, Placebo
Drug
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

NCT01899144
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax, ProAir HFA, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

NCT00685022
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
3
States / cities
Encinitas, California • North Dartmouth, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD

NCT03480997
View directory record Official record
Conditions
COPD
Interventions
Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
Combination Product
Lead sponsor
Pneuma Respiratory, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 24, 2026, 8:21 PM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

NCT04901715
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
Albuterol, Technetium99m - Sulfur Colloid (Tc99m-SC)
Drug · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

NCT04207840
View directory record Official record
Conditions
Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions
Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
Combination Product
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 24, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

NCT02584257
View directory record Official record
Conditions
Mild Persistent Asthma
Interventions
methacholine chloride, placebo ProAir HFA, ProAir HFA, Lupin albuterol HFA MDI, placebo Lupin albuterol HFA MDI
Other · Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
17
States / cities
Huntington Beach, California • Mission Viejo, California • Rolling Hills Estates, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 24, 2026, 8:21 PM EDT